Palisade Bio, Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Palisade Bio is in Stage 4, the downtrend phase, now in week 3 (since Oct 5, 2026). It closed at $1.35, 51.8% below its 52-week high and below its 200-day average, which is falling.

$1.35

-4.06% today

$235M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PALI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S4 18w

S4 59w

S2 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 1w → S4 17w → S1 4w → S4 18w → S1 3w → S4 59w → S1 7w → S4 3w → S1 1w → S2 15w → S3 10w → S2 9w → S3 5w → S4 1w → S3 1w → S2 7w → S3 1w → S4 3w current

Total tracked: 164 weeks across 18 stage runs.

PALI among Biotechnology257th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…257	PALIPalisade Bio, Inc.	Stage 4 · wk 3	37	−15.6%

vs 52W High

-51.8%

$1.34 lo$2.80 hi

51.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-27.9%

200 DMA: $1.87 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.41x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.6%

-30.8%

-37.8%

YTD

-46.0%

-23.7%

Scan Membership

Breakout Watch

Latest: 2021-01-12

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.41x

2026-10-21S4

Wk 3 · Vol 0.49x

2026-10-20S4

Wk 3 · Vol 1.05x

2026-10-19S4

Wk 3 · Vol 0.69x

2026-10-16S4

Wk 2 · Vol 1.50x

2026-10-15S4

Wk 2 · Vol 0.70x

2026-10-14S4

Wk 2 · Vol 1.64x

2026-10-13S4

Wk 2 · Vol 0.63x

2026-10-12S4

Wk 2 · Vol 0.62x

2026-10-09S4

Wk 1 · Vol 0.73x

2026-10-08S4

Wk 1 · Vol 0.83x

2026-10-07S4

Wk 1 · Vol 0.33x

Moving averages & range

50 DMA

$1.76

200 DMA

$1.87

52W High

$2.80

52W Low

$1.34

5D Low

$1.34

Resistance levels (recent highs)

20d High

$1.59

60d High

$2.20

120d High

$2.23

250d High

$2.80

Next resistance

+17.8%

to 20d High

P/E (TTM)

2.3

Forward -4.8

ROE

-51.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.9

Palisade Bio: quick answers

What stage is Palisade Bio in?

As of Oct 22, 2026, Palisade Bio (PALI) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 5, 2026 and is in week 3. What the four stages mean

Is Palisade Bio in an uptrend?

No. Palisade Bio is in a Stage 4 downtrend. It trades 27.9% below its 200-day average, which is falling.

How far is Palisade Bio from its 52-week high?

Palisade Bio closed at $1.35 on Oct 22, 2026, 51.8% below its 52-week high of $2.80. Its 52-week low is $1.34.

How has Palisade Bio performed over the past year?

As of Oct 22, 2026, Palisade Bio is down 23.7% over the past year and down 46.0% so far in 2026.

Which sector and industry is Palisade Bio in?

Palisade Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.